Navidea to Present at Upcoming Investor Conferences

Download as PDF

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that management will present at two upcoming investor conferences. An audio webcast of each presentation will be available live at the URL links noted below. An archived version of the webcasts will be available approximately two hours following the presentations and can be accessed within the Investors' section of the Navidea website http://ir.navidea.com.

2016 Aegis Growth Conference in Las Vegas on Thursday, September 22, 2016 at 9:30 a.m., Pacific Time (12:30 p.m. ET). Webcast Link: http://wsw.com/webcast/aegis3/navb

Ladenburg Thalmann 2016 Healthcare Conference in New York on Tuesday, September 27, 2016 at 4:00 p.m., Eastern Time. Webcast link: http://wsw.com/webcast/ladenburg2/navb

About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. The development activities of the Manocept immunotherapeutic platform will be conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals
Investors & Media:
Sharon Correia, 978-655-2686
Senior Director, Corporate Communications

Source: Navidea Biopharmaceuticals, Inc.

Released September 14, 2016